IPRs: Lessons Learned
This Sterne Kessler webinar will provide insights regarding significant aspects of post-grant proceedings at the Patent Trial and Appeal Board (PTAB) including:
The institution rates and trial outcomes for these proceedings, which are largely driven by inter partes reviews (IPRs), and will include a review of the data from pharma and biotech industry IPRs;
The importance of the post-grant proceeding petition, key considerations on which a patent challenger should focus when preparing its petition, and when and how a patent owner can and should respond to these key considerations; and
An overview of post-grant proceedings on appeal and predictions for these proceedings in the pharma and biotech industry going forward.
- California Tackles Big Pharma’s Anticompetitive ‘Pay for Delay’ Practices That Slow Down Lower-Cost Generic Drug Development
- Personalized Cancer Therapy Found Nonobvious
- Federal Circuit Reverses PTAB Finding Tarceva® Method of Treatment Claims Invalid for Lack of Reasonable Expectation of Success Based on over 99.5% Failure Rate among Treatment Candidates